MedTrace Logo

Study of Letrozole in Recurrent Gliomas

NCT03122197 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.

Conditions

Interventions

DRUG

Letrozole Oral Tablet

Administration: Letrozole will be given orally once daily.

DRUG

Temozolomide

50 mg/m2 TMZ administered orally once daily

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Trisha Wise-Draper, MD, PhD · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-16
Primary Completion
2027-09-01
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122197 on ClinicalTrials.gov